NASDAQ:LNTH Lantheus (LNTH) Stock Price, News & Analysis $112.71 -0.24 (-0.21%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$112.31▼$115.6550-Day Range$77.70▼$123.6252-Week Range$50.20▼$126.89Volume688,791 shsAverage Volume1.06 million shsMarket Capitalization$7.81 billionP/E Ratio17.21Dividend YieldN/APrice Target$120.57 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Lantheus alerts: Email Address Lantheus MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside7.0% Upside$120.57 Price TargetShort InterestBearish6.61% of Shares Sold ShortDividend StrengthN/ASustainability-1.67Upright™ Environmental ScoreNews Sentiment1.00Based on 15 Articles This WeekInsider TradingSelling Shares$3.77 M Sold Last QuarterProj. Earnings Growth7.28%From $6.46 to $6.93 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.31 out of 5 starsMedical Sector152nd out of 936 stocksDiagnostic Substances Industry3rd out of 15 stocks 2.4 Analyst's Opinion Consensus RatingLantheus has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageLantheus has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Lantheus' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.61% of the outstanding shares of Lantheus have been sold short.Short Interest Ratio / Days to CoverLantheus has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Lantheus has recently increased by 4.81%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldLantheus does not currently pay a dividend.Dividend GrowthLantheus does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreLantheus has received a 61.07% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for cancer", "Diagnostic radiopharmaceuticals", and "Therapeutic radiopharmaceuticals" products. See details.Environmental SustainabilityThe Environmental Impact score for Lantheus is -1.67. Previous Next 3.9 News and Social Media Coverage News SentimentLantheus has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Lantheus this week, compared to 6 articles on an average week.Search Interest29 people have searched for LNTH on MarketBeat in the last 30 days. This is an increase of 107% compared to the previous 30 days.MarketBeat Follows13 people have added Lantheus to their MarketBeat watchlist in the last 30 days. This is an increase of 44% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lantheus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,769,262.00 in company stock.Percentage Held by InsidersOnly 1.50% of the stock of Lantheus is held by insiders.Percentage Held by Institutions99.06% of the stock of Lantheus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lantheus' insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Lantheus are expected to grow by 7.28% in the coming year, from $6.46 to $6.93 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lantheus is 17.21, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 140.19.Price to Earnings Ratio vs. SectorThe P/E ratio of Lantheus is 17.21, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 146.66.Price to Book Value per Share RatioLantheus has a P/B Ratio of 9.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Lantheus' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Lantheus Stock (NASDAQ:LNTH)Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Read More LNTH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LNTH Stock News HeadlinesJuly 18, 2024 | insidertrades.comLantheus Holdings, Inc. (NASDAQ:LNTH) CAO Andrea Sabens Sells 341 SharesJuly 15, 2024 | marketbeat.comMassive Breakout: This ETF Signals Big Gains for Small-Cap Stocks (LNTH)The IWM ETF broke above multi-year resistance last week, driven by lower-than-expected June inflation data, leading to a weekly gain of 6.11%.July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 13, 2024 | insidertrades.comInsider Selling: Lantheus Holdings, Inc. (NASDAQ:LNTH) Director Sells 12,530 Shares of StockJuly 26 at 5:57 PM | markets.businessinsider.comLantheus Holdings Set for Growth: Regulatory Tailwinds and Innovative Pipeline Drive Buy RatingJuly 26 at 6:08 AM | markets.businessinsider.comBuy Rating Affirmed for Lantheus Holdings on Positive CMS Policy Update and Undervalued Growth PotentialJuly 26 at 1:46 AM | americanbankingnews.comLantheus Holdings, Inc. (NASDAQ:LNTH) Receives $113.86 Consensus Price Target from BrokeragesJuly 20, 2024 | americanbankingnews.comFY2025 EPS Estimates for Lantheus Holdings, Inc. Boosted by Analyst (NASDAQ:LNTH)July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 19, 2024 | markets.businessinsider.comBuy Rating Affirmed for Lantheus Holdings with Enhanced Revenue Projections and Strategic ExpansionJuly 19, 2024 | markets.businessinsider.comJefferies Reaffirms Their Buy Rating on Lantheus (LNTH)July 18, 2024 | americanbankingnews.comLantheus (NASDAQ:LNTH) Hits New 1-Year High at $126.54July 17, 2024 | globenewswire.comLantheus to Host Second Quarter 2024 Earnings Conference Call and Webcast on July 31, 2024, at 8:00 a.m. Eastern TimeJuly 16, 2024 | americanbankingnews.comLantheus Holdings, Inc. (NASDAQ:LNTH) to Post FY2025 Earnings of $6.61 Per Share, Leerink Partnrs ForecastsJuly 15, 2024 | globenewswire.comLantheus Acquires NAV-4694, a Next-Generation ß Amyloid PET Imaging Agent for Alzheimer's DiseaseJuly 12, 2024 | seekingalpha.comLantheus' Strategic Advantage Amplified By New CMS Payment Refinements (Rating Upgrade)July 10, 2024 | globenewswire.comLantheus Welcomes CMS' Proposed CY25 Rule for Improved Payment for Specialized Diagnostic Radiopharmaceuticals to Support Patient AccessJuly 10, 2024 | fool.comWhy Lantheus Holdings Stock Is Skyrocketing TodaySee More Headlines Receive LNTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lantheus and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today7/26/2024Next Earnings (Confirmed)7/31/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LNTH CUSIPN/A CIK1521036 Webwww.lantheus.com Phone(978) 671-8001Fax978-671-8860Employees700Year FoundedN/APrice Target and Rating Average Stock Price Target$120.57 High Stock Price Target$146.00 Low Stock Price Target$100.00 Potential Upside/Downside+7.0%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)$6.55 Trailing P/E Ratio17.21 Forward P/E Ratio17.45 P/E GrowthN/ANet Income$326.66 million Net Margins33.72% Pretax Margin43.45% Return on Equity54.10% Return on Assets25.70% Debt Debt-to-Equity Ratio0.59 Current Ratio4.84 Quick Ratio4.55 Sales & Book Value Annual Sales$1.30 billion Price / Sales6.03 Cash Flow$6.69 per share Price / Cash Flow16.85 Book Value$11.91 per share Price / Book9.46Miscellaneous Outstanding Shares69,310,000Free Float68,273,000Market Cap$7.81 billion OptionableOptionable Beta0.51 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Brian A. Markison (Age 65)CEO & Director Comp: $139.19kMr. Paul M. Blanchfield (Age 42)President Comp: $1.18MMr. Robert J. Marshall Jr. (Age 57)CFA, CFO & Treasurer Comp: $1.3MMr. Daniel M. Niedzwiecki (Age 46)Chief Administrative Officer, General Counsel & Corporate Secretary Comp: $920.09kDr. Jean-Claude Provost M.D.Chief Medical OfficerMs. Andrea Sabens (Age 45)Chief Accounting Officer Ms. Dorothy BarrSenior Vice President of Manufacturing & Technical OperationsMr. Mark Richard KinarneySenior Director of Investor RelationsMs. Linda S. Lennox (Age 58)VP of Corporate Communications & Chief of Staff Ms. Carol Walker (Age 61)Senior Vice President of Quality More ExecutivesKey CompetitorsNeogenNASDAQ:NEOGRiot PlatformsNASDAQ:RIOTCelldex TherapeuticsNASDAQ:CLDXIntellia TherapeuticsNASDAQ:NTLAMyriad GeneticsNASDAQ:MYGNView All CompetitorsInsiders & InstitutionsAllspring Global Investments Holdings LLCBought 35,069 shares on 7/26/2024Ownership: 0.178%State of Michigan Retirement SystemSold 100 shares on 7/26/2024Ownership: 0.024%Legato Capital Management LLCBought 15,117 shares on 7/26/2024Ownership: 0.022%Mitsubishi UFJ Asset Management UK Ltd.Bought 2,800 shares on 7/26/2024Ownership: 0.004%Tributary Capital Management LLCSold 200 shares on 7/25/2024Ownership: 0.006%View All Insider TransactionsView All Institutional Transactions LNTH Stock Analysis - Frequently Asked Questions How have LNTH shares performed this year? Lantheus' stock was trading at $62.00 at the beginning of 2024. Since then, LNTH stock has increased by 81.8% and is now trading at $112.71. View the best growth stocks for 2024 here. How were Lantheus' earnings last quarter? Lantheus Holdings, Inc. (NASDAQ:LNTH) released its quarterly earnings results on Thursday, May, 2nd. The medical equipment provider reported $1.51 EPS for the quarter, beating the consensus estimate of $1.40 by $0.11. The medical equipment provider earned $369.98 million during the quarter, compared to analysts' expectations of $349.46 million. Lantheus had a trailing twelve-month return on equity of 54.10% and a net margin of 33.72%. What is Mary Anne Heino's approval rating as Lantheus' CEO? 4 employees have rated Lantheus Chief Executive Officer Mary Anne Heino on Glassdoor.com. Mary Anne Heino has an approval rating of 51% among the company's employees. This puts Mary Anne Heino in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. When did Lantheus IPO? Lantheus (LNTH) raised $75 million in an initial public offering on Thursday, June 25th 2015. The company issued 7,900,000 shares at $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Baird was co-manager. Who are Lantheus' major shareholders? Lantheus' top institutional investors include Reinhart Partners LLC. (2.12%), Swedbank AB (0.86%), Allspring Global Investments Holdings LLC (0.18%) and MinichMacGregor Wealth Management LLC (0.14%). Insiders that own company stock include Lantheus Alpha Therapy, Llc, Mary Anne Heino, Robert J Jr Marshall, Paul Blanchfield, Daniel Niedzwiecki, Etienne Montagut, Andrea Sabens, Gerard Ber, Heinz Christoph Maeusli, Brian A Markison, Gary J Pruden, Minnie Baylor-Henry and Carol Walker. View institutional ownership trends. How do I buy shares of Lantheus? Shares of LNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Lantheus own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lantheus investors own include (MBBYF) (MBBYF), Energy Transfer (ET), Paratek Pharmaceuticals (PRTK), Catalyst Pharmaceuticals (CPRX), Amicus Therapeutics (FOLD), Anavex Life Sciences (AVXL) and Exelixis (EXEL). This page (NASDAQ:LNTH) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lantheus Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lantheus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
